Evaluation of a Novel Compression Resistant Matrix for Recombinant Human Bone Morphogenetic Protein-2 (RHBMO-2) for Onlay Graft Indications

Hdl Handle:
http://hdl.handle.net/10675.2/318843
Title:
Evaluation of a Novel Compression Resistant Matrix for Recombinant Human Bone Morphogenetic Protein-2 (RHBMO-2) for Onlay Graft Indications
Authors:
Lu, Sheldon
Abstract:
The discovery and subsequent characterization of endogenous signaling peptides known as bone morphogenetic proteins (BMPs) capable of inducing de novo bone formation in postfetal life represents a critical advancement in the understanding of tissue morphogenesis and has become an incentive to develop additional growth factor based tissue engineering strategies (Wozney & Seeherman 2004). Because BMPs act locally, a suitable carrier system must be used to ensure effective presentation of an adequate dose to a target site (Mont et al. 2004). A number of candidate biomaterials have thus been tested as potential carrier technologies (Huang et al. 2008). Currently, recombinant human BMP-2 (rhBMP-2) coupled with an absorbable collagen sponge (ACS) manufactured from bovine Achilles tendon Type 1 collagen is the only FDA approved device for orthopedic and craniofacial indications. Although the rhBMP-2/ACS construct has demonstrated clinical efficacy for indications including spine fusion, long bone fracture healing, sinus and alveolar augmentation, the ACS’s inability to resist tissue compression limits its use for onlay indications (Wikesjö et al. 2007).
Affiliation:
Department of Oral Biology
Issue Date:
4-Jun-2014
URI:
http://hdl.handle.net/10675.2/318843
Type:
Thesis
Language:
en
Appears in Collections:
Theses and Dissertations

Full metadata record

DC FieldValue Language
dc.contributor.authorLu, Sheldonen
dc.date.accessioned2014-06-04T02:39:13Z-
dc.date.available2014-06-04T02:39:13Z-
dc.date.issued2014-06-04-
dc.identifier.urihttp://hdl.handle.net/10675.2/318843-
dc.description.abstractThe discovery and subsequent characterization of endogenous signaling peptides known as bone morphogenetic proteins (BMPs) capable of inducing de novo bone formation in postfetal life represents a critical advancement in the understanding of tissue morphogenesis and has become an incentive to develop additional growth factor based tissue engineering strategies (Wozney & Seeherman 2004). Because BMPs act locally, a suitable carrier system must be used to ensure effective presentation of an adequate dose to a target site (Mont et al. 2004). A number of candidate biomaterials have thus been tested as potential carrier technologies (Huang et al. 2008). Currently, recombinant human BMP-2 (rhBMP-2) coupled with an absorbable collagen sponge (ACS) manufactured from bovine Achilles tendon Type 1 collagen is the only FDA approved device for orthopedic and craniofacial indications. Although the rhBMP-2/ACS construct has demonstrated clinical efficacy for indications including spine fusion, long bone fracture healing, sinus and alveolar augmentation, the ACS’s inability to resist tissue compression limits its use for onlay indications (Wikesjö et al. 2007).en
dc.language.isoenen
dc.rightsCopyright protected. Unauthorized reproduction or use beyond the exceptions granted by the Fair Use clause of U.S. Copyright law may violate federal law.-
dc.subjectBMPsen
dc.subjectPostfetalen
dc.subjectrecombinant human BMP-2en
dc.subjectabsorbable collagen spongeen
dc.titleEvaluation of a Novel Compression Resistant Matrix for Recombinant Human Bone Morphogenetic Protein-2 (RHBMO-2) for Onlay Graft Indicationsen
dc.typeThesisen
dc.contributor.departmentDepartment of Oral Biology-
dc.description.advisorWikesjo, Ulfen
dc.description.committeeBisch, Frederick; Dixon, Douglas; Lewis, Jillen
All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.